Dr. Jennifer Dahne received her Ph.D. in Clinical Psychology from the University of Maryland, College Park in 2016. She completed her predoctoral internship at the Medical University of South Carolina/Ralph H. Johnson VA Medical Center and her postdoctoral fellowship via MUSC's National Institute on Drug Abuse (NIDA) T32 training program. Dr. Dahne subsequently joined the MUSC faculty in 2018 and she is currently an Associate Professor, affiliated both with the Addiction Sciences Division of the Department of Psychiatry and with the Hollings Cancer Center, Cancer Control Program. The overarching goal of Dr. Dahne's research program is to significantly reduce the public health impact of tobacco use, with a specific focus on cigarette smoking among vulnerable populations (e.g. socioeconomically disadvantaged adults, individuals with additional physical and mental health comorbidities). The majority of Dr. Dahne's work centers around development and evaluation of technology-based remote interventions for the treatment of smoking cessation and common comorbidities (e.g. depression). Dr. Dahne also currently serves as Co-Director of MUSC's Remote & Virtual Trials Program and has interests in developing methods to improve the feasibility and rigor of remote trials. Dr. Dahne is a current NIDA K23 recipient and is also PI of a NIDA-funded R41, a National Cancer Institute-funded R21, and a National Institute of Mental Health-funded R42. She is also an active collaborator on several NIH-funded projects focused on smoking cessation and telehealth intervention delivery.
